Growth and Sexual Maturation During Long-Term Treatment With Risperidone

Dunbar, Fiona; Kusumakar, Vivek; Daneman, Denis; Schulz, Miklos

doi:10.1176/appi.ajp.161.5.918

Cited by 62 publications

(25 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The group with hyperprolactinemia did not differ in pubertal stage from the group without hyperprolactinemia. An earlier 1-year follow-up study of mainly male (80%) children with DBD (n = 222, mean age 11.9 ± 1.4 years) starting prolactin-elevating medication showed no difference in the progression of stages of puberty [24]. When we compared the data of our total study group in attaining the 50th percentile of Tanner stage of puberty with the normative data, the adolescents in the present study were 1.6 years late.…”

Section: Discussionmentioning

confidence: 99%

Antipsychotic-Induced Hyperprolactinemia and Testosterone Levels in Boys

Roke

Harten

Buitelaar³

et al. 2012

Horm Res Paediatr

View full text Add to dashboard Cite

Aims: This cross-sectional study investigatesthe effect of antipsychotic (AP)-induced hyperprolactinemia on testosterone, luteinizing hormone (LH), follicle-stimulating hormone (FSH), inhibin B, and puberty in boys with mainly autism spectrum disorders (ASD). Method: One hundred and four physically healthy 10- to 19-year-old boys with ASD or disruptive behavior disorder (DBD) were recruited between October 2006 and November 2009. Fifty-six adolescents had been treated with AP for >16 months; 48 had never been exposed to AP. Morning non-fasting levels of serum prolactin, testosterone, LH, FSH and inhibin B were obtained and Tanner pubertal stage was determined. Patients with hyperprolactinemia (n = 28) were compared to those without hyperprolactinemia (n = 76) using non-parametric or parametric tests, as appropriate. Results: Patients with AP-induced hyperprolactinemia had significantly lower testosterone levels with adjustment for age (p = 0.035) compared to patients without hyperprolactinemia and without AP treatment. The difference was not significant within the AP-treated group, and the level of testosterone was within the reference range compared to age- and gender-matched normative data. There was no between-group difference for LH, FSH, inhibin B or Tanner stages. Conclusion: AP-induced hyperprolactinemia is related to significantly lower testosterone levels in pubertal boys with ASD and DBD.

show abstract

Section: Discussionmentioning

confidence: 99%

Antipsychotic-Induced Hyperprolactinemia and Testosterone Levels in Boys

Roke

Harten

Buitelaar³

et al. 2012

Horm Res Paediatr

View full text Add to dashboard Cite

show abstract

“…Hyperprolactinemia is usually transient in nature (Findling et al, 2003), but should be closely monitored because of its potential impact on growth and sexual maturation. A recent meta-analysis, however, concluded that there was no evidence of statistically or clinically significant growth failure or delay in pubertal onset or progression in children during risperidone treatment for up to 1 year (Dunbar, Kusumakar, Daneman, & Schultz, 2004). Metabolic AEs such as glucose dysregulation or lipid abnormalities can be related to weight gain or occur independently.…”

Section: Discussionmentioning

confidence: 99%

Risperidone Improves Behavioral Symptoms in Children with Autism in a Randomized, Double-Blind, Placebo-Controlled Trial

Pandina

Bossie

Youssef

et al. 2006

J Autism Dev Disord

Self Cite

123

View full text Add to dashboard Cite

Subgroup analysis of children (5-12 years) with autism enrolled in an 8-week, double-blind, placebo-controlled trial of risperidone for pervasive developmental disorders. The primary efficacy measure was the Aberrant Behavior Checklist-Irritability (ABC-I) subscale. Data were available for 55 children given risperidone (n=27) or placebo (n=28); mean baseline ABC-I ( +/- SD) was 20.6 (8.1) and 21.6 (10.2). Risperidone [mean dose ( +/- SD): 1.37 mg/day (0.7)] resulted in significantly greater reduction from baseline to endpoint in ABC-I versus placebo [mean change ( +/- SD): -13.4 (1.5) vs. -7.2 (1.4), P<0.05; ES=-0.7]. The most common adverse effect with risperidone was somnolence (74% vs. 7% with placebo). Risperidone treatment was well tolerated and significantly improved behavioral problems associated with autism.

show abstract

“…22,33,34 In the analysis of safety of its use for long periods of time, five studies investigated the use of risperidone in a total of 700 children and adolescents aged 5 to 15 years and found no influence on growth or sexual maturity, although there were changes in the levels of prolactin. 35 A retrospective study including 80 individuals with autism who used risperidone to control aggression or impulsivity found that over 60% had a positive result after six months of treatment. The most common adverse effect was weight gain, followed by drowsiness, the adverse event most often associated with treatment discontinuation.…”

Section: Risperidonementioning

confidence: 99%

Atypical antipsychotics in the treatment of pathological aggression in children and adolescents: literature review and clinical recommendations

Teixeira

Jacintho

Celeri

et al. 2013

Trends Psychiatry Psychother.

View full text Add to dashboard Cite

Objective: To review the literature about the use of atypical antipsychotics in the treatment of pathological aggression in children and adolescents. Method: The databases MEDLINE, SciELO, and LILACS were searched for publications in Portuguese or English from 1992 to August 2011 using the following keywords: mental disease, child, adolescent, treatment, atypical antipsychotic, aggressive behavior, aggression, and violent behavior. Results: Sixty-seven studies of good methodological quality and clinical interest and relevance were identified. Studies including children and adolescents were relatively limited, because few atypical antipsychotics have been approved by the Food and Drug Administration (FDA). All the medications included in this review (risperidone, olanzapine, quetiapine, ziprasidone, aripiprazole and clozapine) have some effectiveness in treating aggression in children and adolescents, and choices should be based on clinical indications and side effects. Conclusions: There are few studies about the effectiveness and safety of atypical antipsychotics for the pediatric population, and further randomized controlled studies with larger groups of patients and more diagnostic categories, such as severe conduct disorder and oppositional defiant disorder, should be conducted to confirm the results reported up to date and to evaluate the impact of long-term use. Keywords: Aggression, violence, atypical antipsychotics, behavioral disorders, children, adolescents. ResumoObjetivo: Realizar uma revisão sistemática da literatura científica sobre o uso de antipsicóticos atípicos (APAs) no tratamento da agressividade patológica em crianças e adolescentes. Método: Foi realizada busca eletrônica nas bases de dados MEDLINE, SciELO e LILACS, de 1992 a agosto 2011, considerando artigos publicados em língua inglesa e portuguesa. Foram utilizadas associações das seguintes expressões: mental disease, child, adolescent, treatment, atypical antipsychotic, aggressive behaviour, aggression e violent behavior. Resultados: Foram identificados 67 artigos de boa qualidade metodológica, de relevância e interesse clínico para o tema em foco. De modo geral, os estudos são relativamente limitados para esta faixa etária, resultado do fato de poucos APAs terem sido aprovados pela Food and Drug Administration (FDA). Dentre as medicações consideradas nesta revisão (risperidona, olanzapina, quetiapina, ziprazidona, aripiprazol e clozapina), todas elas podem ter alguma efetividade no tratamento da agressividade em crianças e adolescentes, ficando a escolha baseada na indicação clínica e perfil de efeitos colaterais. Conclusão: O número ainda limitado de estudos acerca da efetividade e segurança na população pediátrica demanda pesquisas futuras com grupos maiores de pacientes e com mais categorias diagnósticas (como, por exemplo, as formas graves de transtorno de conduta e transtorno desafiador de oposição), desenhadas de forma randomizada e controlada. Assim poderão ser confirmados os achados até o momento e o impacto do uso em lo...

show abstract

Growth and Sexual Maturation During Long-Term Treatment With Risperidone

Abstract: In this retrospective analysis, there was no evidence of statistically or clinically significant growth failure or delay in pubertal onset or progression in children treated for up to 1 year with risperidone.

Cited by 62 publications

References 7 publications

Antipsychotic-Induced Hyperprolactinemia and Testosterone Levels in Boys

Antipsychotic-Induced Hyperprolactinemia and Testosterone Levels in Boys

Risperidone Improves Behavioral Symptoms in Children with Autism in a Randomized, Double-Blind, Placebo-Controlled Trial

Atypical antipsychotics in the treatment of pathological aggression in children and adolescents: literature review and clinical recommendations

Contact Info

Product

Resources

About